S2Medical

0,01 SEK

+5,38 %

Mindre end 1K følgere

S2M

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Dividend

Investorkonsensus

+5,38 %

0,00 %

-8,41 %

-8,41 %

-17,65 %

-6,67 %

-94,56 %

-99,28 %

-99,73 %

S2Medical operates in the medical technology sector. The company is focused on research and development of various wound healing products. Various products offered include cellulose-based materials and dressings for the healing of burns and chronic wounds. The products are sold under various brands, mainly at a European level. S2Medical was founded in 2013 and is headquartered in Linköping.

Markedsværdi

9,18 mio. SEK

Aktieomsætning

2,58 t SEK

Omsætning

14,36 mio.

EBIT %

-18,54 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

5.6

2026

Generalforsamling '26

21.8

2026

Delårsrapport Q2'26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Selskabsmeddelelse20.6.2024, 08.32

S2Medical AB: Epiprotect® Demonstrates Significantly Lower Infection Risk in Major Pediatric Study

Selskabsmeddelelse6.11.2023, 15.09

S2Medical AB (publ) Signs Exclusive Distribution Agreement with Provas Medical Ltd for the Turkish Market

Selskabsmeddelelse25.8.2023, 13.30

S2Medical AB: INTERIM REPORT APRIL - JUNE 2023

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse5.7.2023, 06.45

S2Medical AB (publ) announces final outcome in the company's rights issue

Selskabsmeddelelse4.7.2023, 08.21

S2Medical AB Secures New Loan Agreement and Aims to be Debt-Free by July 2024

Selskabsmeddelelse3.7.2023, 16.26

S2Medical AB: S2Medical (publ) announces preliminary outcome in the company's rights issue

Selskabsmeddelelse16.6.2023, 11.45

S2Medical AB (publ) publishes a prospectus regarding the rights issue

Selskabsmeddelelse8.6.2023, 15.15

S2Medical AB (publ) signs a manufacturing agreement with a distributor in Saudi Arabia

Selskabsmeddelelse31.5.2023, 17.00

S2Medical AB: Interim Report January - March 2023

Selskabsmeddelelse17.5.2023, 11.33

S2Medical AB (publ) signs a distribution agreement for the Iranian market

Selskabsmeddelelse16.5.2023, 14.45

S2Medical AB: S2Medical wins procurement for wound healing items in the Västra Götaland region

Selskabsmeddelelse10.5.2023, 09.34

S2Medical AB: Postponing of publication of the quarterly report for the period January to March 2023

Selskabsmeddelelse24.4.2023, 15.09

S2Medical AB: Postponement of publication of annual report

Selskabsmeddelelse21.4.2023, 13.37

S2Medical AB: S2Medical wins procurement for wound healing items in the United Arab Emirates worth approximately SEK 3.4 million

Selskabsmeddelelse13.4.2023, 09.32

S2Medical AB (publ) signs a distributor agreement in the United Arab Emirates and delivers a record order of the skin substitute Epiprotect worth about SEK 2 million

Selskabsmeddelelse28.3.2023, 14.36

S2Medical AB: S2Medical implements a strategic change to reach profitability faster

Selskabsmeddelelse3.3.2023, 11.39

S2Medical AB: S2Medical wins procurement for wound healing equipment in Region Halland

Selskabsmeddelelse22.2.2023, 14.45

Year-end report January - December 2022 S2Medical AB (publ)

Selskabsmeddelelse16.2.2023, 16.44

S2Medical AB: Postponing of publication of the year-end report

Selskabsmeddelelse2.1.2023, 16.15

S2Medical AB: Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.